RJA
INSY

Raymond James & Associates’s Insys Therapeutics, Inc. INSY Stock Holding History

Raymond James & Associates’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,683
Closed -$138K – 3777
2018
Q3 		$138K Sell
13,683
-4,800
-26% -$38.3K ﹤0.01% 3386
2018
Q2 		$134K Buy
18,483
+250
+1% +$1.74K ﹤0.01% 3354
2018
Q1 		$110K Sell
18,233
-12,775
-41% -$105K ﹤0.01% 3254
2017
Q4 		$298K Buy
31,008
+14,982
+93% +$98K ﹤0.01% 2836
2017
Q3 		$142K Buy
16,026
+4,024
+34% +$41.5K ﹤0.01% 3132
2017
Q2 		$152K Buy
+12,002
New +$142K ﹤0.01% 3054
2016
Q4 		– Sell
-12,116
Closed -$143K – 3413
2016
Q3 		$143K Buy
+12,116
New +$184K ﹤0.01% 2939
2015
Q4 		– Sell
-13,184
Closed -$375K – 2431
2015
Q3 		$375K Sell
13,184
-1,647
-11% -$60.6K ﹤0.01% 2048
2015
Q2 		$533K Sell
14,831
-6,961
-32% -$217K ﹤0.01% 2063
2015
Q1 		$633K Buy
+21,792
New +$576K ﹤0.01% 1924
2014
Q4 		– Sell
-51,880
Closed -$1.01M – 2347
2014
Q3 		$1.01M Buy
51,880
+12,120
+30% +$190K 0.01% 1491
2014
Q2 		$621K Buy
+39,760
New +$643K ﹤0.01% 1748

Other funds holding INSY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Raymond James & Associates's INSY Position: Q4 2018 in Review

Raymond James & Associates sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 13,683 shares — an estimated $138K sold.

Raymond James & Associates first reported a position in INSY in Q2 2014 and held it in 12 quarters. The position peaked at $1.01M in Q3 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • Raymond James & Associates reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Raymond James & Associates sold 13,683 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $138K.
  • Raymond James & Associates first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 12 quarters.
  • Raymond James & Associates's Insys Therapeutics, Inc. position peaked at $1.01M in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.